MarketCap
Facebook
X
Telegram
Taro Pharmaceutical Industries Ltd. Income Statement 2023-2008 | TARO
Brief overview of financial results at Taro Pharmaceutical Industries Ltd.
The comparison covers a five-year financial horizon. According to figures from Taro Pharmaceutical Industries Ltd., revenue changed from 662 million dollars to 573 million dollars over five years. The cumulative result was −13.4%, corresponding to roughly −2.8% per year. The business finished the period with a smaller revenue base.
The five-year change in gross profit reached −42.1%: from 464 million dollars to 268 million dollars. Direct costs outpaced revenue, limiting the benefit of changes in sales. Gross margin moved from 70% to 46.8%. The margin decline reflects a less favorable sales-and-cost structure.
EBITDA was $320 million at the beginning and $49.8 million at the end of the period (−84.4%). EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from 48.3% to 8.7%. The margin contraction indicates weaker operating efficiency.
The net result moved from 211 million dollars to 25.4 million dollars, or −87.9%. The decline reduces the quality of the financial trajectory.
What the figures show
The results contain several connected negative signals. The weaker side of the profile includes a lower gross margin, a weaker final result and a softer top-line trend. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Taro Pharmaceutical Industries Ltd.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 1.36 B | 1.87 B | 2.75 B | 2.63 B | 3.59 B | 3.54 B | 4.49 B | 5.42 B | 5.84 B | 4.35 B | 2.22 B | 1.47 B | - | - | - |
Shares |
37.6 M | 37.6 M | 38.2 M | 38.5 M | 39 M | 40.2 M | 41.3 M | 42.8 M | 42.8 M | 44.3 M | 44.7 M | 44.5 M | 44.4 M | 40.3 K | 39.2 M | - |
Historical Prices |
36 | 48.9 | 71.5 | 67.3 | 89.4 | 85.7 | 105 | 127 | 132 | 97.5 | 49.8 | 33.2 | ||||
Net Income |
25.4 M | 58.3 M | -387 M | 244 M | 282 M | 211 M | 456 M | 541 M | 484 M | 360 M | 266 M | 47.3 M | 183 M | 64.1 M | 114 M | - |
Revenue |
573 M | 561 M | 549 M | 645 M | 670 M | 662 M | 879 M | 951 M | 863 M | 759 M | 671 M | 145 M | 506 M | - | - | - |
Cost of Revenue |
305 M | 268 M | 252 M | 245 M | 224 M | 198 M | 208 M | 170 M | 186 M | 179 M | 176 M | 46 M | 176 M | 159 M | 147 M | - |
Gross Profit |
268 M | 293 M | 297 M | 400 M | 446 M | 464 M | 671 M | 779 M | 677 M | 580 M | 495 M | 99.2 M | 330 M | 233 M | 209 M | - |
Operating Income |
17.7 M | 63.5 M | -414 M | 247 M | 296 M | 303 M | 515 M | 614 M | 528 M | 430 M | 329 M | 66.2 M | 205 M | 89.1 M | 71.8 M | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | -94 K | 251 K | 755 K | 548 K | - |
EBITDA |
49.8 M | 89.4 M | -390 M | 268 M | 315 M | 320 M | 530 M | 629 M | 543 M | 447 M | 346 M | 70.8 M | 223 M | 108 M | 90.3 M | - |
Operating Expenses |
251 M | 230 M | 710 M | 153 M | 150 M | 160 M | 156 M | 164 M | 149 M | 150 M | 166 M | 32.9 M | 125 M | 144 M | 137 M | - |
General and Administrative Expenses |
85.1 M | 57.1 M | 52.8 M | 56.8 M | 43.9 M | 44.6 M | 34.4 M | 33.3 M | 34.7 M | 35.6 M | 35.3 M | 8.74 M | 44.4 M | 59.4 M | 100 M | - |
All numbers in USD currency
Quarterly Income Statement Taro Pharmaceutical Industries Ltd.
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2009-Q4 | 2008-Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
37.6 M | - | - | - | 37.6 M | - | - | - | 38.2 M | - | - | - | 38.5 M | - | - | - | 39 M | - | - | - | 40.2 M | - | - | - | 41.3 M | - | - | - | 42.8 M | - | - | - | 42.8 M | - | - | - | 44.3 M | - | - | - | 44.7 M | - | - | - | 44.5 M | 44.4 M | - | - | 44.3 M | 40.3 K | 39.2 M | - |
Net Income |
25.4 M | - | - | - | 58.3 M | - | - | - | -387 M | - | - | - | 244 M | - | - | - | 282 M | - | - | - | 211 M | - | - | - | 456 M | - | - | - | 541 M | - | - | - | 484 M | - | - | - | 360 M | - | - | - | 266 M | - | - | - | 47.3 M | 183 M | - | - | 25.7 M | 64.1 M | 114 M | - |
Revenue |
573 M | - | - | - | 561 M | - | - | - | 549 M | - | - | - | 645 M | - | - | - | 670 M | - | - | - | 662 M | - | - | - | 879 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 145 M | - | - | - | 108 M | - | - | - |
Cost of Revenue |
305 M | - | - | - | 268 M | - | - | - | 252 M | - | - | - | 245 M | - | - | - | 224 M | - | - | - | 198 M | - | - | - | 208 M | - | - | - | 170 M | - | - | - | 186 M | - | - | - | 179 M | - | - | - | 176 M | - | - | - | 46 M | 176 M | - | - | 44.6 M | 159 M | 147 M | - |
Gross Profit |
268 M | - | - | - | 293 M | - | - | - | 297 M | - | - | - | 400 M | - | - | - | 446 M | - | - | - | 464 M | - | - | - | 671 M | - | - | - | 779 M | - | - | - | 677 M | - | - | - | 580 M | - | - | - | 495 M | - | - | - | 99.2 M | 330 M | - | - | 63.1 M | 233 M | 209 M | - |
Operating Income |
17.7 M | - | - | - | 63.5 M | - | - | - | -414 M | - | - | - | 247 M | - | - | - | 296 M | - | - | - | 303 M | - | - | - | 515 M | - | - | - | 614 M | - | - | - | 528 M | - | - | - | 430 M | - | - | - | 329 M | - | - | - | 66.2 M | 205 M | - | - | 33.4 M | 89.1 M | 71.8 M | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -94 K | 609 K | - | - | 251 K | 755 K | 548 K | - |
EBITDA |
49.8 M | - | - | - | 89.4 M | - | - | - | -390 M | - | - | - | 268 M | - | - | - | 315 M | - | - | - | 320 M | - | - | - | 530 M | - | - | - | 629 M | - | - | - | 543 M | - | - | - | 447 M | - | - | - | 346 M | - | - | - | 70.8 M | 223 M | - | - | 38.1 M | 108 M | 90.3 M | - |
Operating Expenses |
251 M | - | - | - | 230 M | - | - | - | 710 M | - | - | - | 153 M | - | - | - | 150 M | - | - | - | 160 M | - | - | - | 156 M | - | - | - | 164 M | - | - | - | 149 M | - | - | - | 150 M | - | - | - | 166 M | - | - | - | 32.9 M | 125 M | - | - | 29.7 M | 144 M | 137 M | - |
General and Administrative Expenses |
85.1 M | - | - | - | 57.1 M | - | - | - | 52.8 M | - | - | - | 56.8 M | - | - | - | 43.9 M | - | - | - | 44.6 M | - | - | - | 34.4 M | - | - | - | 33.3 M | - | - | - | 34.7 M | - | - | - | 35.6 M | - | - | - | 35.3 M | - | - | - | 8.74 M | 44.4 M | - | - | 22.5 M | 59.4 M | 100 M | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Taro Pharmaceutical Industries Ltd. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
